The effects of PDK4 on DLBCL cell growth and rituximab sensitivity were further supported by our in vitro and in vivo data that PDK4 OE tumors grow faster and show less response to treatment with rituximab. This evidence concerns the gene PDK4 and diffuse large B-cell lymphoma.